Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Privately-held US generic drugmaker Breckenridge Pharmaceutical has entered into an agreement to acquire from Pernix Therapeutics (NYSE: PTX) certain assets from its subsidiary, Cypress Pharmaceutical, for $30 million. 12 August 2013
Generics
US health care company Perrigo (NYSE: PRGO) revealed this morning that Ireland-based drugmaker Elan Corp (NYSE: ELN) has entered into a definitive agreement to a takeover offer of $6.25 in case and 0.07636 shares of "New Perrigo" for each share of Elan, valuing each Elan share at $16.50 based on their July 26 closing pric 29 July 2013
Generics
Generic drugmaker Perrigo (NYSE: PRGO) says it has signed a definitive agreement to acquire and has completed the acquisition of an ophthalmic sterile ointment and solution Abbreviated New Drug Application product portfolio from fellow USA-based privately held Fera Pharmaceuticals. 18 June 2013
Generics
Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk and Novozymes, has purchased all shares of the Norwegian firm Xellia Pharmaceutical for around $700 million from 3i and other current shareholders. As a consequence of the transaction, Xellia will revert to Danish ownership with headquarters in Copenhagen. 21 May 2013
Generics
US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma to settle all outstanding patent litigation related to Actavis' generic version of the currently marketed abuse-deterrent formulation of OxyContin (oxycodone), a narcotic pain reliever. 29 April 2013
Generics
Further to its announcement last month that it was undertaking a review of the strategic options for its global Injectables business (The Pharma Letter March 4), Jordon-based Hikma Pharmaceuticals (LSE: HIK) says that it has concluded this strategic review and has determined that this business should remain part of the Hikma Group. The business had been said to be possibly worth $2.2 billion by analysts. 17 April 2013
Generics
German family-owned firm Merz Pharma has written to the board of director of Obagi Medical Products outlining a proposal to acquire all of the outstanding common stock of Obagi for $22 per share (around $383.5 in total) in cash. This proposal represents a 58% premium to Obagi's closing share price on March 14, 2013, and 11% higher than the $19.75 ($344 million) takeover offer from Canada's Valeant Pharmaceuticals (TSX: VRX) announced last month (The Pharma Letter March 20). 2 April 2013
Generics
The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating its earlier decision to revoke pharma behemoth Pfizer's (NYSE:PFE) patent for kidney cancer agent Sutent (sunitinib) in India, Cipla counsel and managing partner of the law firm Singh & Singh, Prathiba Singh, told the local newspaper Business Standard. 12 February 2013
Generics
South Africa's largest health care company Adcock Ingram (AIP: SJ) has announced the completion of the acquisition of Cosme Farma Laboratories, a pan-Indian pharmaceutical company based in Goa, India for 745 million rupees ($12.7 million). The deal was announced last summer (The Pharma Letter July 10, 2012) and is aimed at expanding the company's presence in the high-growth $16 billion Indian pharmaceutical market. 22 January 2013
Generics
The biggest non-event in the Japan health care market during 2013 will be no reimbursement price reductions, comments P Reed Maurer, long-time Japanese pharma industry watcher and president of International Alliances Limited (IAL). In fact, the next price revisions will not occur until April 2014. 3 January 2013
Generics
US drugmaker Perrigo (Nasdaq: PRGO; TASE) announced on Friday that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, a privately-held, Chicago, Illinois-based drug development company, for around $45 million on a cash free and debt free basis. 31 December 2012
Generics
Dublin, Ireland-based sales, marketing, distribution and business support services group DCC, says that its DCC Healthcare unit has reached conditional agreement to acquire privately held Kent Pharmaceutical, a UK generic pharmaceuticals company, based on an enterprise valuation of 71.2 million euros ($93.3 million). Completion of the acquisition is conditional, inter alia, on approval from the Irish Competition Authority and it is anticipated that the transaction will complete in early 2013. 24 December 2012
Generics
Want to acquire a Japanese pharmaceutical company? Join the back of a long line of companies with the same objective. There is no shortage of willing buyers, but trying to find a willing seller is like looking for a needle in a haystack, says P Reed Maurer, long-time Japanese pharma industry watcher and president of International Alliances Limited (IAL) in an exclusive article for The Pharma Letter. 18 December 2012
Generics
Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), has entered into a definitive agreement with Caraco Pharmaceutical Laboratories, a wholly-owned subsidiary of India's Sun Pharmaceutical Industries (SUN: BO) for the sale of the non-Colcrys (colchicine, USP) URL Pharma, generic business. 17 December 2012
Generics
Anglo-Swedish drug major AstraZeneca (LSE: AZ) said on Friday that the US Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the US substance patent protecting the firm's blockbuster cholesterol drug Crestor (rosuvastatin calcium) (RE37,314 - the '314 patent) is valid and enforceable. 17 December 2012
Generics
Finland-based water chemistry specialist Kemira Oyj (OMX: KRA1V) has signed an agreement to sell its food and pharmaceutical businesses together with its acetate based chemicals business to US company Niacet Corp, for a transaction value of 82 million euros ($106 million). 16 December 2012
Generics
Indian drugmaker Elder Pharmaceuticals says it is ready to enter the European Union market following receipt of Certificate of Suitability (CoS) from European Directorate for the Quality of Medicines and Healthcare for its active pharmaceutical ingredient (API) diosmin, an oral phlebotropic drug used in the treatment of venous system related diseases, reports the Indian Express. 26 November 2012
Generics
Impax Laboratories (Nasdaq: IPXL) said yesterday that it plans to collaborate with fellow US drugmaker Perrigo (Nasdaq: PRGO) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed. 22 November 2012
Generics
USA-based Validus Pharmaceuticals (NYSE: VR) together with Wood Creek Capital Management, have acquired USs rights to six well-known product lines, patent protection on which has now expired, from the US subsidiary of Swiss drug major Novartis (NOVN: VX). No financial terms were revealed. 19 November 2012
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze